Philippe Marteau

Active 1990–2025

125
Papers
31,016
Citations
92
h-index
124
i10-index

Citations

Citations per year for Philippe Marteau1991: 2 citations1992: 9 citations1993: 16 citations1994: 15 citations1995: 22 citations1996: 14 citations1997: 36 citations1998: 41 citations1999: 46 citations2000: 64 citations2001: 83 citations2002: 115 citations2003: 121 citations2004: 187 citations2005: 185 citations2006: 219 citations2007: 207 citations2008: 222 citations2009: 217 citations2010: 334 citations2011: 365 citations2012: 375 citations2013: 421 citations2014: 443 citations2015: 396 citations2016: 456 citations2017: 445 citations2018: 391 citations2019: 1,107 citations2020: 1,195 citations2021: 1,075 citations2022: 860 citations2023: 617 citations2024: 814 citations2025: 375 citations2026: 22 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,586 citing papers, 16.5% of this breakdownChina: 1,222 citing papers, 7.8% of this breakdownUnited Kingdom: 1,170 citing papers, 7.5% of this breakdownFrance: 1,092 citing papers, 7% of this breakdownItaly: 911 citing papers, 5.8% of this breakdownCanada: 789 citing papers, 5% of this breakdownNetherlands: 677 citing papers, 4.3% of this breakdownGermany: 651 citing papers, 4.2% of this breakdownSpain: 522 citing papers, 3.3% of this breakdownBelgium: 481 citing papers, 3.1% of this breakdownAustralia: 449 citing papers, 2.9% of this breakdownJapan: 364 citing papers, 2.3% of this breakdown
0%16.5%Other 30.3%

Fields

  • Biochemistry, Genetics and Molecular Biology54.5%
  • Medicine23.8%
  • Agricultural and Biological Sciences11%
  • Nursing4.7%
  • Immunology and Microbiology2.1%
  • Environmental Science1.1%
  • Other2.8%

Topics

  • Gut microbiota and health15.7%
  • Inflammatory Bowel Disease10.8%
  • Probiotics and Fermented Foods7.3%
  • Clostridium difficile and Clostridium perfringens research5.3%
  • Microscopic Colitis4.3%
  • Gastrointestinal motility and disorders3.5%
  • Other53.1%

Coauthors

All papers

Open in search
  1. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

    Authors: , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 4,325

  2. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Silvio Danese, Julián Panés, Guillaume Bouguen, Sarah O’Donnell, Benjamin Pariente, Shawn Winer, Stephen B. Hanauer, J -F Colombel - The American Journal of Gastroenterology 2015 cited by 1,838

  3. Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Microbiome 2020 cited by 364

  4. Low counts of Faecalibacterium prausnitzii in colitis microbiota

    Authors: , , , , , , , , , - Inflammatory Bowel Diseases 2009 cited by 1,254

  5. Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity

    Authors: , , , , , , , , , , , , , , , , - Gastroenterology 2013 cited by 446

  6. A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis

    Authors: , , , , , , , , , , - Gastroenterology 2006 cited by 1,208

  7. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marc Lémann - The Lancet 2012 cited by 642

  8. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon

    Authors: , , , , , , , - Gut 2003 cited by 739

  9. Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Gut Microbes 2022 cited by 59

  10. Saccharomyces boulardii Does Not Prevent Relapse of Crohn's Disease

    Authors: , , , , , , , , , , , - Clinical Gastroenterology and Hepatology 2013 cited by 184

  11. One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Alimentary Pharmacology & Therapeutics 2017 cited by 177

  12. Safety of Probiotics That Contain Lactobacilli or Bifidobacteria

    Authors: , , , , , , - Clinical Infectious Diseases 2003 cited by 554

  13. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial

    Authors: , , , , , , , , , , , , , , , , , , - Gut 2005 cited by 411

  14. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus

    Authors: , , , , , , , , , - Alimentary Pharmacology & Therapeutics 2017 cited by 153

  15. Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery

    Authors: , , , , , , , , , , , - Gut 2015 cited by 157

  16. Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study

    Authors: , , , , , , , , - Immunity & Ageing 2015 cited by 147

  17. Dysbiosis in inflammatory bowel disease: a role for bacteriophages?

    Authors: , , , , , - Gut 2008 cited by 243

  18. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

    Authors: , , , , , , , , , - Gut 2005 cited by 365

  19. A neural network algorithm for detection of GI angiectasia during small-bowel capsule endoscopy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Gastrointestinal Endoscopy 2018 cited by 207

  20. A computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation products

    Authors: , , , , , , , , - Applied Microbiology and Biotechnology 1999 cited by 453

  21. Specificities of the fecal microbiota in inflammatory bowel disease

    Authors: , , , , , , , - Inflammatory Bowel Diseases 2006 cited by 436

  22. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bas Oldenburg, Yoram Bouhnik, Ralf Kießlich, Eduard F. Stange, Simon Travis, James O. Lindsay - Journal of Crohn s and Colitis 2009 cited by 897

  23. FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease

    Authors: , , , , , , , , , - Gastroenterology 2011 cited by 365

  24. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects

    Authors: , - Best Practice & Research Clinical Gastroenterology 2003 cited by 190